No open-access location is known for this record yet.
No open-access location is known for this record yet.
The hematologic mission and scope of the Journal in 2013: Blood, a podium for clinical studies and a podium for experimental research in hematology Medical and biological science is progressing, and this informs the role and position of modern scientific journals.In the face of a growing number of submissions to Blood representing increasingly diverse content, we feel that it has become important to revisit the orientation of the Journal.Every week, the Editors receive presubmission inquiries from investigators about their scientific work: "Is our work suitable for Blood?" "Does it fit the scope of the Journal?"Against this background, we briefly readdress here the focus of Blood.The directional thrust of the Journal is hematologic.The Journal strives to publish studies of high impact, novelty, originality, and quality that we believe will be of the greatest interest to our readers who represent all areas of hematology.Blood has a major commitment to reporting studies on clinical effectiveness in hematology.This includes traditional randomized and nonrandomized trials, studies with adaptive trial designs and sophisticated surrogate end points, observational studies, metaanalyses, diagnostic studies, preventive studies, and clinical studies correlating outcomes with molecular or animal data.We are particularly interested in studies that are likely to influence patterns of care.This area has always been, and continues to be, a priority for the Journal.The Journal welcomes interesting clinical studies in any hematologic subdiscipline, including those that address clinical issues in hemostasis, thrombosis and vascular medicine, red or white blood cell disorders, or therapeutic trials in leukemia, myeloma, and lymphoma.We aim to provide practice-changing data to our many readers in clinical practice who treat patients with hematologic disease on a day-to-day basis.Maintaining a rapid review time is a priority for Blood.First review of new submissions is completed within an average of 21 days, and fast-track reviews are usually completed in less than 10 days; we are constantly striving to improve our performance in this regard.For investigators engaged in ongoing clinical trials of broad interest, we suggest that it may be useful to notify the Editors at an early stage, so that a pathway of expedited review can be set.We welcome clinical studies and would like to increase our publication of them.The Journal has a special position among hematology publications in that it offers a platform for both clinical and basic and experimental studies.The Journal publishes experimental animal and in vitro cell biological research that reveals new mechanistic insights into physiological and pathological processes in hematology.Blood has acquired a unique position as a journal because it represents the whole of hematology.Now, the "under one roof" principle is perhaps more relevant and attractive than ever before.The ongoing explosion
Loading…
Imported from OpenAlex (CC0) — nothing here is generated.